Congenital cytomegalovirus - current state of knowledge on the treatment and prevention of fetuses and newborns
DOI:
https://doi.org/10.12775/QS.2025.37.57297Keywords
Cytomegalovirus, CMV, congenital CMV, Hiperimmunoglobilin, Valacyclovir, Valgancyclovir, Newborn, Infant, Pregnancy, FetusAbstract
Cytomegalovirus (CMV) is common pathogen in the human population and one of the most causes of intrauterine infections of the fetus. It is a component of the acronym TORCH describing pathogens which are a significant risk factor for miscarrings or serious damage to the fetus. Symptomatic congenital cytomegalovirus occurs in about 10% of infected newborns and, among of the other things, can cause hearing loosing, vision impairment or cognitive impairment in the children. Importantly, a child who is asymptomatic at the time of delivery is still at risk of developing dysfunctions in the future. Currently there is no effective vaccine against cytomegalovirus. There are attempts to treat pregnant women with antiviral drugs and hyperimmunoglobulins. The treatment is intended to protect the fetus from vertical transmission of the virus or to reduce the effects of infection. An important aspect is the time of starting treatment for the woman and the seroprevalence of expectant mothers. The risk of fetal infection increases with the age of pregnancy. Primary infection of the mother poses a greater danger to the fetus than secondary infection. The key moment of treatment apear to be the first trimester of pregnancy, because it is during this period that the greatest devastation occurs in the rapidly developing fetus. For this reason, the greatest benefit from treatment may be obtained by pregnant women with primary CMV infection in the first trimester of pregnancy. In this article, we will present the problem of congenital cytomegalovirus and describe the current proposals for treatment and prophylaxis used in fetuses and newborns infected with cytomegalovirus, we will present the current state of knowledge about potential side effects of its use.
References
1. Sobolewska-Pilarczyk M, Rajewski P, Rajewski P. Cytomegalia wrodzona — aktualne zalecenia dotyczące diagnostyki i terapii. Forum Medycyny Rodzinnej. 2016;10(6):309-13.
2. Pokorska-Śpiewak M, Niezgoda A, Gołkowska M, Czech-Kowalska J, Gruszfeld D, Dobrzańska A, et al. Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious Diseases. Przegląd Epidemiologiczny - Epidemiological Review. 2016;70(2):297-310.
3. Kabani N, Ross SA. Congenital Cytomegalovirus Infection. The Journal of Infectious Diseases. 2020;221(Supplement_1):S9-S14.
4. Pesch MH, Saunders NA, Abdelnabi S. Cytomegalovirus Infection in Pregnancy: Prevention, Presentation, Management and Neonatal Outcomes. J Midwifery Womens Health. 2021;66(3):397-402.
5. Ross SA, Kimberlin D. Clinical outcome and the role of antivirals in congenital cytomegalovirus infection. Antiviral Research. 2021;191:105083.
6. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355-63.
7. Leruez-Ville M, Sellier Y, Salomon LJ, Stirnemann JJ, Jacquemard F, Ville Y. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort. Clin Infect Dis. 2013;56(10):1428-35.
8. Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol. 2006;35(2):216-20.
9. Enders G, Daiminger A, Bäder U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol. 2011;52(3):244-6.
10. Shet A. Congenital and perinatal infections: throwing new light with an old TORCH. Indian J Pediatr. 2011;78(1):88-95.
11. Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. American Journal of Obstetrics and Gynecology. 2020;223(6):870-83.e11.
12. Puhakka L, Renko M, Helminen M, Peltola V, Heiskanen-Kosma T, Lappalainen M, et al. Primary versus non-primary maternal cytomegalovirus infection as a cause of symptomatic congenital infection - register-based study from Finland. Infect Dis (Lond). 2017;49(6):445-53.
13. Leber Amy L. Maternal and congenital human cytomegalovirus infection: laboratory testing for detection and diagnosis. Journal of Clinical Microbiology. 2024;62(4):e00313-23.
14. D'Alberti E, Rizzo G, Khalil A, Mappa I, Pietrolucci ME, Capannolo G, et al. Counseling in fetal medicine: Congenital cytomegalovirus infection. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2024;295:8-17.
15. Pinninti S, Boppana S. Antiviral Treatment of Maternal and Congenital Cytomegalovirus (CMV) Infections. Viruses [Internet]. 2023; 15(10).
16. Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, Akram M, Riaz M, Rasool G, et al. A review: Mechanism of action of antiviral drugs. International Journal of Immunopathology and Pharmacology. 2021;35:20587384211002621.
17. Leruez-Ville M, Chatzakis C, Lilleri D, Blazquez-Gamero D, Alarcon A, Bourgon N, et al. Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). The Lancet Regional Health – Europe. 2024;40.
18. D'Antonio F, Marinceu D, Prasad S, Khalil A. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2023;61(4):436-44.
19. Shahar-Nissan K, Pardo J, Peled O, Krause I, Bilavsky E, Wiznitzer A, et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. The Lancet. 2020;396(10253):779-85.
20. Zammarchi L, Tomasoni LR, Liuzzi G, Simonazzi G, Dionisi C, Mazzarelli LL, et al. Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study. American Journal of Obstetrics & Gynecology MFM. 2023;5(10):101101.
21. Chatzakis C, Shahar-Nissan K, Faure-Bardon V, Picone O, Hadar E, Amir J, et al. American Journal of Obstetrics & Gynecology. 2024;230(2):109-17.e2.
22. Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. American Journal of Obstetrics and Gynecology. 2020;223(3):330-49.
23. Amir J, Chodick G, Pardo J. Revised Protocol for Secondary Prevention of Congenital Cytomegalovirus Infection With Valaciclovir Following Infection in Early Pregnancy. Clinical Infectious Diseases. 2023;77(3):467-71.
24. Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933-43.
25. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients. Transplantation. 2005;79(11).
26. Carmona AS, Kakkar F, Gantt S. Perinatal Cytomegalovirus Infection. Curr Treat Options Pediatr. 2022;8(4):395-411.
27. Nicloux M, Peterman L, Parodi M, Magny JF. Outcome and management of newborns with congenital cytomegalovirus infection. Arch Pediatr. 2020;27(3):160-5.
28. van Gent R, Metselaar HJ, Kwekkeboom J. Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection. Transplant Rev (Orlando). 2017;31(2):78-86.
29. Bartlett AW, Hamilton ST, Shand AW, Rawlinson WD. Fetal therapies for cytomegalovirus: What we tell prospective parents. Prenat Diagn. 2020;40(13):1681-92.
30. Seidel V, Hackelöer M, Rancourt RC, Henrich W, Siedentopf JP. Fetal and maternal outcome after hyperimmunoglobulin administration for prevention of maternal-fetal transmission of cytomegalovirus during pregnancy: retrospective cohort analysis. Arch Gynecol Obstet. 2020;302(6):1353-9.
31. Minsart AF, Smiljkovic M, Renaud C, Gagné MP, Lamarre V, Kakkar F, et al. Use of Cytomegalovirus-Specific Hyperimmunoglobulins in Pregnancy: A Retrospective Cohort. J Obstet Gynaecol Can. 2018;40(11):1409-16.
32. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350-62.
33. Hughes Brenna L, Clifton Rebecca G, Rouse Dwight J, Saade George R, Dinsmoor Mara J, Reddy Uma M, et al. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. New England Journal of Medicine. 2021;385(5):436-44.
34. Blázquez-Gamero D, Galindo Izquierdo A, Del Rosal T, Baquero-Artigao F, Izquierdo Méndez N, Soriano-Ramos M, et al. Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: a multicenter study in Madrid. J Matern Fetal Neonatal Med. 2019;32(4):617-25.
35. Revello Maria G, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, et al. A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus. New England Journal of Medicine.370(14):1316-26.
36. Struble EB, Murata H, Komatsu T, Scott D. Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection. Int J Mol Sci. 2021;22(16).
37. Kagan KO, Enders M, Schampera MS, Baeumel E, Hoopmann M, Geipel A, et al. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol. 2019;53(3):383-9.
38. Kagan KO, Enders M, Hoopmann M, Geipel A, Simonini C, Berg C, et al. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol. 2021;57(4):560-7.
39. Penka L, Kagan KO, Goelz R, Hamprecht K. Comparison of quantitative real-time PCR and short-term (18-hour) microculture in diagnosis of fetal cytomegalovirus infection: Impact of hyperimmunoglobulin treatment. Prenat Diagn. 2018;38(12):936-42.
40. Devlieger R, Buxmann H, Nigro G, Enders M, Jückstock J, Siklós P, et al. Serial Monitoring and Hyperimmunoglobulin versus Standard of Care to Prevent Congenital Cytomegalovirus Infection: A Phase III Randomized Trial. Fetal Diagn Ther. 2021;48(8):611-23.
41. Schirwani-Hartl N, Palmrich P, Haberl C, Perkmann-Nagele N, Kiss H, Berger A, et al. Biweekly Versus Monthly Hyperimmune Globulin Therapy for Primary Cytomegalovirus Infection in Pregnancy. J Clin Med. 2023;12(21).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Katarzyna Grego, Mateusz Grego, Łukasz Stojak, Dariusz Popiela, Karina Urbańska, Filip Kwiatkowski, Mateusz Baczewski, Witold Czyż
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 27
Number of citations: 0
